| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1517/14712598.1.4.619 |
| P698 | PubMed publication ID | 11727498 |
| P50 | author | Richard Carter | Q89224170 |
| P2093 | author name string | Stowers A | |
| P2860 | cites work | Assembly and expression of a synthetic gene encoding the antigen Pfs48/45 of the human malaria parasite Plasmodium falciparum in yeast | Q47857505 |
| Minimal variation in the transmission-blocking vaccine candidate Pfs48/45 of the human malaria parasite Plasmodium falciparum. | Q48003662 | ||
| Production, purification and immunogenicity of a malaria transmission-blocking vaccine candidate: TBV25H expressed in yeast and purified using nickel-NTA agarose | Q48004480 | ||
| Strain polymorphism of Plasmodium falciparum transmission-blocking target antigen Pfs230. | Q48014503 | ||
| Comparison of Plasmodium yoelii ookinete surface antigens with human and avian malaria parasite homologues reveals two highly conserved regions | Q48037075 | ||
| Plasmodium falciparum: An abundant stage-specific protein expressed during early gametocyte development | Q57044263 | ||
| Cloning and expression of the gene for Plasmodium falciparum transmission-blocking target antigen, Pfs230 | Q30042991 | ||
| Differential ability of specific regions of Plasmodium falciparum sexual-stage antigen, Pfs230, to induce malaria transmission-blocking immunity | Q30042993 | ||
| Immune effector mechanisms in malaria | Q33711422 | ||
| Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes | Q34005142 | ||
| Adjuvant-dependent immune response to malarial transmission-blocking vaccine candidate antigens | Q36231958 | ||
| Transmission-blocking activity of a chitinase inhibitor and activation of malarial parasite chitinase by mosquito protease | Q36289280 | ||
| Target antigens of transmission-blocking immunity on gametes of plasmodium falciparum | Q36348052 | ||
| Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito | Q36351262 | ||
| Restricted or absent immune responses in human populations to plasmodium falciparum gamete antigens that are targets of malaria transmission-blocking antibodies | Q36355913 | ||
| Impact on malaria morbidity of a programme supplying insecticide treated nets in children aged under 2 years in Tanzania: community cross sectional study | Q37133983 | ||
| Malaria parasite chitinase and penetration of the mosquito peritrophic membrane | Q37463006 | ||
| Identification of a continuous and cross-reacting epitope for Plasmodium falciparum transmission-blocking immunity | Q37611409 | ||
| Evidence for a mass community effect of insecticide-treated bednets on the incidence of malaria on the Kenyan coast | Q39120636 | ||
| Transmission-blocking vaccines: uses and current status of development | Q39122635 | ||
| Plasmodium falciparum sexual stage antigens: Immunogenicity and cell-mediated responses | Q39511780 | ||
| Transmission-blocking immunity against malaria and other vector-borne diseases | Q40769782 | ||
| Plasmodium falciparum: heterologous synthesis of the transmission-blocking vaccine candidate Pfs48/45 in recombinant vaccinia virus-infected cells | Q41003251 | ||
| Recombinant Pfs25 protein of plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals | Q42006764 | ||
| Successful immunization against the sexual stages of Plasmodium gallinaceum | Q42979860 | ||
| Malaria transmission blocked by immunisation with gametes of the malaria parasite | Q42979953 | ||
| Induction of plasmodium falciparum transmission-blocking antibodies by recombinant vaccinia virus | Q43409506 | ||
| A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains | Q43525538 | ||
| Single amino acid variation in the ookinete vaccine antigen from field isolates of Plasmodium falciparum | Q43775261 | ||
| Minimal variation in a vaccine candidate from the sexual stage of plasmodium falciparum | Q44023350 | ||
| Association between anti-Pfs48/45 reactivity and P. falciparum transmission-blocking activity in sera from Cameroon | Q44137386 | ||
| Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. | Q44138863 | ||
| Transmission-blocking immunity to Plasmodium falciparum in malaria-immune individuals is associated with antibodies to the gamete surface protein Pfs230. | Q44142097 | ||
| Properties of epitopes of pfs 48/45, a target of transmission blocking monoclonal antibodies, on gametes of different isolates of plasmodium falciparum | Q44143594 | ||
| Antibodies to plasmodium falciparum gamete surface antigens in papua new guinea sera | Q44150700 | ||
| Transmission-blocking antibodies against multiple, non-variant target epitopes of the Plasmodium falciparum gamete surface antigen Pfs230 are all complement-fixing | Q44168384 | ||
| Human immune recognition of recombinant proteins representing discrete domains of the Plasmodium falciparum gamete surface protein, Pfs230. | Q44169334 | ||
| Recombinant Pfs230, a Plasmodium falciparum gametocyte protein, induces antisera that reduce the infectivity of Plasmodium falciparum to mosquitoes | Q44173322 | ||
| Disruption of the Pfg27 locus by homologous recombination leads to loss of the sexual phenotype in P. falciparum | Q47849362 | ||
| Identification of additional members define a Plasmodium falciparum gene superfamily which includes Pfs48/45 and Pfs230. | Q47850151 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria vaccine | Q6741353 |
| malaria transmission | Q56928847 | ||
| P304 | page(s) | 619-628 | |
| P577 | publication date | 2001-07-01 | |
| P1433 | published in | Expert Opinion on Biological Therapy | Q5421201 |
| P1476 | title | Current developments in malaria transmission-blocking vaccines | |
| P478 | volume | 1 |
| Q28740771 | A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activity |
| Q40223307 | Accelerated and long term stability study of Pfs25-EPA conjugates adjuvanted with Alhydrogel®. |
| Q37259973 | Analysis of von Willebrand factor A domain-related protein (WARP) polymorphism in temperate and tropical Plasmodium vivax field isolates |
| Q35783861 | Carboxypeptidases B of Anopheles gambiae as targets for a Plasmodium falciparum transmission-blocking vaccine. |
| Q34077952 | Challenges and approaches for mosquito targeted malaria control |
| Q36670217 | Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice |
| Q36228960 | Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen |
| Q57274840 | Estado actual de la malaria (y II): obstáculos hacia la eliminación y desafíos desde el punto de vista de la investigación |
| Q30982324 | Evaluation of the standard membrane feeding assay (SMFA) for the determination of malaria transmission-reducing activity using empirical data. |
| Q44150427 | Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials |
| Q34999437 | Functional characterisation of sexual stage specific proteins in Plasmodium falciparum |
| Q44153250 | Functional immunogenicity of baculovirus expressing Pfs25, a human malaria transmission-blocking vaccine candidate antigen |
| Q33922779 | Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells |
| Q35143303 | Helminth vaccines: from mining genomic information for vaccine targets to systems used for protein expression |
| Q36967832 | Human C5a Protein Participates in the Mosquito Immune Response Against Dengue Virus. |
| Q36393216 | Identification of candidate transmission-blocking antigen genes in Theileria annulata and related vector-borne apicomplexan parasites |
| Q40259888 | Immune Responses in Malaria |
| Q63493282 | Immune Responses to the Sexual Stages of Parasites |
| Q39679346 | Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission |
| Q36795388 | Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America. |
| Q35017744 | Malaria vaccines: where are we and where are we going? |
| Q36428352 | Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation |
| Q36594040 | Murine model for assessment of Plasmodium falciparum transmission-blocking vaccine using transgenic Plasmodium berghei parasites expressing the target antigen Pfs25. |
| Q36213215 | New ultrastructural analysis of the invasive apparatus of the Plasmodium ookinete |
| Q44164504 | Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria |
| Q37549510 | Plasmodium berghei HAP2 induces strong malaria transmission-blocking immunity in vivo and in vitro |
| Q27974514 | Plasmodium ookinete-secreted proteins secreted through a common micronemal pathway are targets of blocking malaria transmission |
| Q27973462 | Proteins of the malaria parasite sexual stages: expression, function and potential for transmission blocking strategies |
| Q38818196 | Recognition of Plasmodium falciparum mature gametocyte-infected erythrocytes by antibodies of semi-immune adults and malaria-exposed children from Gabon |
| Q30432107 | Sequence polymorphisms in Pvs48/45 and Pvs47 gametocyte and gamete surface proteins in Plasmodium vivax isolated in Korea |
| Q44149598 | Spatial simulation of malaria transmission and its control by malaria transmission blocking vaccination |
| Q43048714 | Synthetic propeptide inhibits mosquito midgut chitinase and blocks sporogonic development of malaria parasite |
| Q30039034 | The Plasmodium berghei sexual stage antigen PSOP12 induces anti-malarial transmission blocking immunity both in vivo and in vitro |
| Q36906724 | Transmission-blocking interventions eliminate malaria from laboratory populations. |
Search more.